$AVNR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AVANIR PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in AVANIR PHARMACEUTICALS, INC.. Get notifications about new insider transactions in AVANIR PHARMACEUTICALS, INC. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Sep 13 2011 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 2.75 | 100,000 | 275,000 | 65,690 | 165.7 K to 65.7 K (-60.35 %) |
May 05 2011 | AVNR | AVANIR PHARMACEUTI ... | Sibold William John | Option Exercise | A | 4.17 | 250,000 | 1,042,500 | 250,000 | ||
May 05 2011 | AVNR | AVANIR PHARMACEUTI ... | Sibold William John | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K | |
Feb 18 2011 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Buy | W | 0.00 | 1,350 | 0 | 40,922 | 39.6 K to 40.9 K (+3.41 %) |
Feb 10 2011 | AVNR | AVANIR PHARMACEUTI ... | Podlesak Dennis | Director | Grant | A | 0.00 | 30,000 | 0 | 238,594 | 208.6 K to 238.6 K (+14.38 %) |
Feb 10 2011 | AVNR | AVANIR PHARMACEUTI ... | Mazzo David J | Director | Grant | A | 0.00 | 30,000 | 0 | 238,594 | 208.6 K to 238.6 K (+14.38 %) |
Feb 10 2011 | AVNR | AVANIR PHARMACEUTI ... | WHEELER CRAIG A | Director | Grant | A | 0.00 | 5,000 | 0 | 302,594 | 297.6 K to 302.6 K (+1.68 %) |
Feb 10 2011 | AVNR | AVANIR PHARMACEUTI ... | WHEELER CRAIG A | Director | Grant | A | 0.00 | 30,000 | 0 | 297,594 | 267.6 K to 297.6 K (+11.21 %) |
Feb 10 2011 | AVNR | AVANIR PHARMACEUTI ... | Whitcup Scott M | Director | Grant | A | 0.00 | 30,000 | 0 | 237,594 | 207.6 K to 237.6 K (+14.45 %) |
Feb 10 2011 | AVNR | AVANIR PHARMACEUTI ... | MATHEWS CHARLES | Director | Grant | A | 0.00 | 30,000 | 0 | 240,094 | 210.1 K to 240.1 K (+14.28 %) |
Feb 10 2011 | AVNR | AVANIR PHARMACEUTI ... | AUSTIN STEPHEN G | Director | Grant | A | 0.00 | 30,000 | 0 | 240,094 | 210.1 K to 240.1 K (+14.28 %) |
Jan 07 2011 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 4.05 | 10,000 | 40,500 | 165,690 | 175.7 K to 165.7 K (-5.69 %) |
Dec 15 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 3.92 | 1,446 | 5,668 | 175,690 | 177.1 K to 175.7 K (-0.82 %) |
Dec 08 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Sell | S | 3.79 | 13,660 | 51,771 | 39,572 | 53.2 K to 39.6 K (-25.66 %) |
Dec 08 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 3.80 | 10,000 | 38,000 | 177,136 | 187.1 K to 177.1 K (-5.34 %) |
Dec 07 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | J | 0.00 | 6,669,204 | 0 | 12 | 6.7 M to 12 (-100.00 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Option Exercise | A | 4.18 | 100,000 | 418,000 | 100,000 | |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Grant | A | 0.00 | 17,500 | 0 | 196,836 | 179.3 K to 196.8 K (+9.76 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Option Exercise | M | 0.88 | 9,000 | 7,920 | 39,000 | |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Option Exercise | M | 1.74 | 14,350 | 24,969 | 115,050 | |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Option Exercise | M | 1.74 | 24,000 | 41,760 | 129,400 | |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Option Exercise | A | 4.18 | 72,500 | 303,050 | 72,500 | |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Sell | S | 4.03 | 9,000 | 36,270 | 53,232 | 62.2 K to 53.2 K (-14.46 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Buy | M | 0.88 | 9,000 | 7,920 | 62,232 | 53.2 K to 62.2 K (+16.91 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Sell | S | 4.03 | 14,350 | 57,831 | 53,232 | 67.6 K to 53.2 K (-21.23 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Buy | M | 1.74 | 14,350 | 24,969 | 67,582 | 53.2 K to 67.6 K (+26.96 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Sell | S | 4.15 | 24,000 | 99,600 | 53,232 | 77.2 K to 53.2 K (-31.08 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Buy | M | 1.74 | 24,000 | 41,760 | 77,232 | 53.2 K to 77.2 K (+45.09 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Grant | A | 0.00 | 11,250 | 0 | 53,232 | 42 K to 53.2 K (+26.80 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Option Exercise | M | 0.53 | 195,300 | 103,509 | 251,100 | |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Option Exercise | A | 4.18 | 400,000 | 1,672,000 | 400,000 | |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 4.08 | 195,300 | 797,254 | 208,352 | 403.7 K to 208.4 K (-48.38 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Buy | M | 0.53 | 195,300 | 103,509 | 403,652 | 208.4 K to 403.7 K (+93.74 %) |
Dec 03 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Grant | A | 0.00 | 62,500 | 0 | 208,352 | 145.9 K to 208.4 K (+42.85 %) |
Nov 10 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | S | 4.81 | 1,200,000 | 5,773,920 | 6,669,216 | 7.9 M to 6.7 M (-15.25 %) |
Nov 10 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | S | 5.10 | 44,626 | 227,593 | 7,869,216 | 7.9 M to 7.9 M (-0.56 %) |
Nov 08 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 4.76 | 10,000 | 47,556 | 187,136 | 197.1 K to 187.1 K (-5.07 %) |
Nov 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | S | 4.80 | 332,572 | 1,597,377 | 7,913,842 | 8.2 M to 7.9 M (-4.03 %) |
Nov 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | S | 4.52 | 1,400,106 | 6,332,539 | 8,246,414 | 9.6 M to 8.2 M (-14.51 %) |
Nov 02 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 5.70 | 20,000 | 114,000 | 145,852 | 165.9 K to 145.9 K (-12.06 %) |
Nov 02 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | S | 4.49 | 1,290,871 | 5,800,400 | 9,646,520 | 10.9 M to 9.6 M (-11.80 %) |
Nov 02 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | S | 5.36 | 2,478,142 | 13,273,424 | 10,937,391 | 13.4 M to 10.9 M (-18.47 %) |
Nov 02 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | S | 5.06 | 1,424,947 | 7,215,647 | 13,415,533 | 14.8 M to 13.4 M (-9.60 %) |
Oct 12 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | S | 3.52 | 311,000 | 1,093,445 | 14,840,480 | 15.2 M to 14.8 M (-2.05 %) |
Oct 12 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | S | 3.47 | 240,838 | 836,792 | 15,151,480 | 15.4 M to 15.2 M (-1.56 %) |
Oct 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 3.23 | 10,000 | 32,269 | 227,036 | 237 K to 227 K (-4.22 %) |
Sep 15 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 2.70 | 1,321 | 3,567 | 165,852 | 167.2 K to 165.9 K (-0.79 %) |
Sep 15 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 2.70 | 1,447 | 3,907 | 237,036 | 238.5 K to 237 K (-0.61 %) |
Sep 08 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 2.70 | 10,000 | 27,034 | 238,483 | 248.5 K to 238.5 K (-4.02 %) |
Sep 02 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 2.83 | 62,874 | 177,864 | 167,173 | 230 K to 167.2 K (-27.33 %) |
Sep 02 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 2.86 | 40,000 | 114,512 | 230,047 | 270 K to 230 K (-14.81 %) |
Aug 20 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 3.08 | 35,000 | 107,664 | 248,483 | 283.5 K to 248.5 K (-12.35 %) |
Aug 13 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Option Exercise | M | 0.88 | 12,000 | 10,560 | 36,000 | |
Aug 13 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Option Exercise | M | 1.20 | 16,250 | 19,500 | 3,750 | |
Aug 13 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Sell | S | 3.10 | 12,581 | 39,001 | 41,982 | 54.6 K to 42 K (-23.06 %) |
Aug 13 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Sell | S | 3.11 | 15,669 | 48,731 | 54,563 | 70.2 K to 54.6 K (-22.31 %) |
Aug 13 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Buy | M | 0.88 | 12,000 | 10,560 | 70,232 | 58.2 K to 70.2 K (+20.61 %) |
Aug 13 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Buy | M | 1.20 | 16,250 | 19,500 | 58,232 | 42 K to 58.2 K (+38.71 %) |
Aug 09 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 3.28 | 10,000 | 32,800 | 283,483 | 293.5 K to 283.5 K (-3.41 %) |
Jul 15 2010 | AVNR | AVANIR PHARMACEUTI ... | Clarus Lifesciences I, L.P. | 10% Owner | Sell | S | 3.53 | 165,000 | 583,143 | 15,392,318 | 15.6 M to 15.4 M (-1.06 %) |
Jul 09 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 3.02 | 10,000 | 30,203 | 293,483 | 303.5 K to 293.5 K (-3.30 %) |
Jun 15 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 2.71 | 1,447 | 3,921 | 303,483 | 304.9 K to 303.5 K (-0.47 %) |
Jun 15 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 2.71 | 1,320 | 3,577 | 270,047 | 271.4 K to 270 K (-0.49 %) |
Jun 08 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 2.38 | 50,000 | 119,115 | 304,930 | 354.9 K to 304.9 K (-14.09 %) |
May 04 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 3.06 | 65,906 | 201,376 | 271,367 | 337.3 K to 271.4 K (-19.54 %) |
May 04 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 3.31 | 40,000 | 132,372 | 337,273 | 377.3 K to 337.3 K (-10.60 %) |
Apr 09 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 3.01 | 10,000 | 30,100 | 377,273 | 387.3 K to 377.3 K (-2.58 %) |
Mar 31 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 2.60 | 30,000 | 78,000 | 387,273 | 417.3 K to 387.3 K (-7.19 %) |
Mar 16 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 2.13 | 1,448 | 3,084 | 354,930 | 356.4 K to 354.9 K (-0.41 %) |
Mar 17 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Sell | S | 2.08 | 200 | 416 | 41,982 | 42.2 K to 42 K (-0.47 %) |
Mar 17 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Sell | S | 2.08 | 11,000 | 22,886 | 42,182 | 53.2 K to 42.2 K (-20.68 %) |
Mar 17 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Sell | S | 2.08 | 100 | 208 | 53,182 | 53.3 K to 53.2 K (-0.19 %) |
Mar 17 2010 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Sell | S | 2.08 | 4,218 | 8,773 | 53,282 | 57.5 K to 53.3 K (-7.34 %) |
Mar 16 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 2.13 | 1,317 | 2,805 | 417,273 | 418.6 K to 417.3 K (-0.31 %) |
Feb 22 2010 | AVNR | AVANIR PHARMACEUTI ... | MATHEWS CHARLES | Director | Grant | A | 0.00 | 40,000 | 0 | 211,969 | 172 K to 212 K (+23.26 %) |
Feb 22 2010 | AVNR | AVANIR PHARMACEUTI ... | AUSTIN STEPHEN G | Director | Grant | A | 0.00 | 40,000 | 0 | 210,094 | 170.1 K to 210.1 K (+23.52 %) |
Feb 22 2010 | AVNR | AVANIR PHARMACEUTI ... | Mazzo David J | Director | Grant | A | 0.00 | 40,000 | 0 | 208,594 | 168.6 K to 208.6 K (+23.73 %) |
Feb 22 2010 | AVNR | AVANIR PHARMACEUTI ... | Podlesak Dennis | Director | Grant | A | 0.00 | 40,000 | 0 | 208,594 | 168.6 K to 208.6 K (+23.73 %) |
Feb 22 2010 | AVNR | AVANIR PHARMACEUTI ... | Whitcup Scott M | Director | Grant | A | 0.00 | 40,000 | 0 | 207,594 | 167.6 K to 207.6 K (+23.87 %) |
Feb 22 2010 | AVNR | AVANIR PHARMACEUTI ... | WHEELER CRAIG A | Director | Grant | A | 0.00 | 40,000 | 0 | 267,594 | 227.6 K to 267.6 K (+17.58 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.96 | 6,000 | 11,766 | 418,001 | 424 K to 418 K (-1.42 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.96 | 2,000 | 3,921 | 424,001 | 426 K to 424 K (-0.47 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.94 | 2,000 | 3,880 | 426,001 | 428 K to 426 K (-0.47 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.94 | 900 | 1,746 | 428,001 | 428.9 K to 428 K (-0.21 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.93 | 100 | 193 | 428,901 | 429 K to 428.9 K (-0.02 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.93 | 3,100 | 5,985 | 429,001 | 432.1 K to 429 K (-0.72 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.93 | 925 | 1,785 | 432,101 | 433 K to 432.1 K (-0.21 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.91 | 1,500 | 2,865 | 433,026 | 434.5 K to 433 K (-0.35 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.90 | 15,000 | 28,508 | 434,526 | 449.5 K to 434.5 K (-3.34 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.90 | 2,600 | 4,940 | 449,526 | 452.1 K to 449.5 K (-0.58 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.88 | 900 | 1,692 | 452,126 | 453 K to 452.1 K (-0.20 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 1.97 | 4,872 | 9,598 | 453,026 | 457.9 K to 453 K (-1.06 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 1.97 | 47,274 | 93,130 | 457,898 | 505.2 K to 457.9 K (-9.36 %) |
Jan 05 2010 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 1.97 | 28,499 | 56,143 | 368,458 | 397 K to 368.5 K (-7.18 %) |
Dec 16 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.84 | 2,000 | 3,680 | 505,172 | 507.2 K to 505.2 K (-0.39 %) |
Dec 16 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.83 | 18,408 | 33,687 | 507,172 | 525.6 K to 507.2 K (-3.50 %) |
Dec 16 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.82 | 2,000 | 3,640 | 525,580 | 527.6 K to 525.6 K (-0.38 %) |
Dec 16 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Sell | S | 1.81 | 14,927 | 27,018 | 527,580 | 542.5 K to 527.6 K (-2.75 %) |
Dec 15 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 1.82 | 1,320 | 2,402 | 542,507 | 543.8 K to 542.5 K (-0.24 %) |
Dec 15 2009 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 1.82 | 1,350 | 2,457 | 396,957 | 398.3 K to 397 K (-0.34 %) |
Nov 30 2009 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Option Exercise | A | 1.74 | 153,400 | 266,916 | 153,400 | |
Nov 30 2009 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Option Exercise | A | 1.74 | 210,900 | 366,966 | 210,900 | |
Nov 30 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Option Exercise | A | 1.74 | 417,600 | 726,624 | 417,600 | |
Oct 13 2009 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Sell | S | 2.23 | 547,135 | 1,220,111 | 7,125,754 | 7.7 M to 7.1 M (-7.13 %) |
Oct 13 2009 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Sell | S | 2.12 | 427,145 | 905,547 | 7,672,889 | 8.1 M to 7.7 M (-5.27 %) |
Oct 13 2009 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Sell | S | 2.46 | 804,712 | 1,979,592 | 8,100,034 | 8.9 M to 8.1 M (-9.04 %) |
Sep 15 2009 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Sell | S | 2.10 | 2,000 | 4,200 | 398,307 | 400.3 K to 398.3 K (-0.50 %) |
Sep 15 2009 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 2.21 | 1,349 | 2,981 | 400,307 | 401.7 K to 400.3 K (-0.34 %) |
Sep 15 2009 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Buy | P | 2.18 | 2,000 | 4,360 | 401,656 | 399.7 K to 401.7 K (+0.50 %) |
Sep 15 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 2.21 | 1,287 | 2,844 | 543,827 | 545.1 K to 543.8 K (-0.24 %) |
Aug 13 2009 | AVNR | AVANIR PHARMACEUTI ... | Vivo Ventures Fund VI, L.P. | 10% Owner | Sell | S | 3.37 | 232,450 | 783,938 | 8,049,553 | 8.3 M to 8 M (-2.81 %) |
Aug 13 2009 | AVNR | AVANIR PHARMACEUTI ... | Vivo Ventures Fund VI, L.P. | 10% Owner | Sell | S | 4.05 | 49,800 | 201,690 | 8,282,003 | 8.3 M to 8.3 M (-0.60 %) |
Aug 13 2009 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Sell | S | 3.58 | 894,120 | 3,200,950 | 8,904,746 | 9.8 M to 8.9 M (-9.12 %) |
Aug 03 2009 | AVNR | AVANIR PHARMACEUTI ... | Vivo Ventures Fund VI, L.P. | 10% Owner | Sell | S | 2.20 | 1,400 | 3,080 | 8,331,803 | 8.3 M to 8.3 M (-0.02 %) |
Aug 03 2009 | AVNR | AVANIR PHARMACEUTI ... | Vivo Ventures Fund VI, L.P. | 10% Owner | Sell | S | 2.29 | 142,366 | 326,445 | 8,333,203 | 8.5 M to 8.3 M (-1.68 %) |
Aug 03 2009 | AVNR | AVANIR PHARMACEUTI ... | Vivo Ventures Fund VI, L.P. | 10% Owner | Sell | S | 2.28 | 145,500 | 331,245 | 8,475,569 | 8.6 M to 8.5 M (-1.69 %) |
Aug 03 2009 | AVNR | AVANIR PHARMACEUTI ... | Vivo Ventures Fund VI, L.P. | 10% Owner | Sell | S | 2.42 | 122,100 | 295,714 | 8,621,069 | 8.7 M to 8.6 M (-1.40 %) |
Jul 17 2009 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 2.13 | 23,425 | 49,895 | 399,656 | 423.1 K to 399.7 K (-5.54 %) |
Jul 17 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 2.13 | 4,749 | 10,115 | 545,114 | 549.9 K to 545.1 K (-0.86 %) |
Jul 17 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 2.13 | 42,292 | 90,082 | 549,863 | 592.2 K to 549.9 K (-7.14 %) |
Jun 15 2009 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 1.31 | 1,217 | 1,594 | 423,081 | 424.3 K to 423.1 K (-0.29 %) |
Jun 15 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 1.31 | 1,287 | 1,686 | 592,155 | 593.4 K to 592.2 K (-0.22 %) |
Mar 17 2009 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 0.45 | 1,440 | 648 | 424,298 | 425.7 K to 424.3 K (-0.34 %) |
Feb 25 2009 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Buy | P | 0.43 | 5,000 | 2,133 | 425,738 | 420.7 K to 425.7 K (+1.19 %) |
Feb 25 2009 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Buy | P | 0.43 | 5,000 | 2,130 | 420,738 | 415.7 K to 420.7 K (+1.20 %) |
Feb 25 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Buy | P | 0.44 | 14,100 | 6,204 | 593,442 | 579.3 K to 593.4 K (+2.43 %) |
Feb 25 2009 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Buy | P | 0.43 | 900 | 387 | 579,342 | 578.4 K to 579.3 K (+0.16 %) |
Feb 25 2009 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Buy | P | 0.44 | 10,900 | 4,796 | 69,400 | 58.5 K to 69.4 K (+18.63 %) |
Feb 25 2009 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Buy | P | 0.42 | 1,000 | 420 | 58,500 | 57.5 K to 58.5 K (+1.74 %) |
Feb 20 2009 | AVNR | AVANIR PHARMACEUTI ... | Whitcup Scott M | Director | Grant | A | 0.00 | 60,000 | 0 | 167,594 | 107.6 K to 167.6 K (+55.77 %) |
Feb 20 2009 | AVNR | AVANIR PHARMACEUTI ... | WHEELER CRAIG A | Director | Grant | A | 0.00 | 120,000 | 0 | 227,594 | 107.6 K to 227.6 K (+111.53 %) |
Feb 20 2009 | AVNR | AVANIR PHARMACEUTI ... | Podlesak Dennis | Director | Grant | A | 0.00 | 60,000 | 0 | 168,594 | 108.6 K to 168.6 K (+55.25 %) |
Feb 20 2009 | AVNR | AVANIR PHARMACEUTI ... | MATHEWS CHARLES | Director | Grant | A | 0.00 | 60,000 | 0 | 171,969 | 112 K to 172 K (+53.59 %) |
Feb 20 2009 | AVNR | AVANIR PHARMACEUTI ... | Mazzo David J | Director | Grant | A | 0.00 | 60,000 | 0 | 168,594 | 108.6 K to 168.6 K (+55.25 %) |
Feb 20 2009 | AVNR | AVANIR PHARMACEUTI ... | AUSTIN STEPHEN G | Director | Grant | A | 0.00 | 60,000 | 0 | 170,094 | 110.1 K to 170.1 K (+54.50 %) |
Dec 18 2008 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Option Exercise | A | 0.53 | 185,000 | 98,050 | 185,000 | |
Dec 18 2008 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Option Exercise | A | 0.53 | 446,400 | 236,592 | 446,400 | |
Dec 18 2008 | AVNR | AVANIR PHARMACEUTI ... | OCAMPO CHRISTINE | Vice President, Fin ... | Option Exercise | A | 0.53 | 130,000 | 68,900 | 130,000 | |
Oct 24 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.48 | 10,600 | 5,088 | 9,798,866 | 9.8 M to 9.8 M (+0.11 %) |
Oct 15 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.49 | 6,465 | 3,168 | 9,788,266 | 9.8 M to 9.8 M (+0.07 %) |
Oct 15 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.50 | 32,300 | 16,150 | 9,781,801 | 9.7 M to 9.8 M (+0.33 %) |
Oct 15 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.45 | 73,551 | 33,098 | 9,749,501 | 9.7 M to 9.7 M (+0.76 %) |
Oct 10 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.48 | 41,385 | 19,865 | 9,675,950 | 9.6 M to 9.7 M (+0.43 %) |
Oct 10 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.50 | 114,384 | 57,192 | 9,634,565 | 9.5 M to 9.6 M (+1.20 %) |
Oct 10 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.48 | 21,318 | 10,233 | 9,520,181 | 9.5 M to 9.5 M (+0.22 %) |
Sep 17 2008 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Sr. VP, Chief Medic ... | Payment of Exercise | F | 0.83 | 1,217 | 1,010 | 415,738 | 417 K to 415.7 K (-0.29 %) |
Sep 17 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.80 | 413,217 | 330,574 | 9,498,863 | 9.1 M to 9.5 M (+4.55 %) |
Sep 17 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.76 | 17,387 | 13,214 | 9,085,646 | 9.1 M to 9.1 M (+0.19 %) |
Sep 17 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.85 | 244,449 | 207,782 | 9,068,259 | 8.8 M to 9.1 M (+2.77 %) |
Sep 10 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.91 | 48,103 | 43,774 | 8,823,810 | 8.8 M to 8.8 M (+0.55 %) |